Eleven babies die after Dutch women given Viagra in drug trial

The Guardian reports that Dutch women who were given Viagra to increase the growth of their unborn child as part of a major drug trial face an anxious wait after the deaths of 11 babies.

The research, carried out at 10 hospitals across the Netherlands, involved women whose placentas had been underperforming taking sildenafil, a medication sold under the brand name Viagra.

Viagra, which dilates the blood vessels, is used for erectile dysfunction in men and is prescribed for people with high blood pressure. The hope, backed up by experimental research on rats, had been that the drug would encourage a better flow of blood through the placenta, promoting the growth of the child.

The pregnant women taking part in the trial all had unborn babies whose growth had been severely limited in the womb. The children’s prognosis, given a lack of available therapy, was regarded as being poor as a result.

The trial was terminated last week when an independent committee overseeing the research discovered that more babies than expected were being born with lung problems.

In total, 93 women were given the drug as part of the trial, led by Amsterdam University Medical Centre. Seventeen babies developed lung problems, and 11 have since died.

Of the 90 women in a control group, who took a placebo, three developed the same lung issues and no babies died.

Between 10 and 15 women are waiting to find out if their child has been affected.

It is feared the drug caused high blood pressure in the lungs, leading to the babies receiving too little oxygen. There is nothing to suggest the trial was mishandled.

In an interview with the Dutch daily newspaper De Volkskrant, the leader of the research, the gynaecologist Wessel Ganzevoort, said: “We wanted to show that this is an effective way to promote the growth of the baby. But the opposite happened. I am shocked. The last thing you want is to harm patients.

The research began in 2015 and was due to run until 2020, with the participation of 350 patients.

A spokesman for Amsterdam UMC said it believed the trial had been conducted properly, but would expect an external investigation to be launched.